Offsetting the gains of financial firms was Flamel Technologies SA (FLML), which agreed to take over specialty drug maker Eclat Pharmaceuticals in a debt-and-warrant deal and named Eclat's chief executive to replace its own CEO. Shares of Flamel tumbled 23% to $5.93.
Flamel Technologies Announces Acquisition of Eclat Pharmaceuticals Mike Anderson appointed Flamel's Chief Executive Officer; Steve Willard resigns as CEO but will remain on Board of Directors http://www.cnbc.com/id/46739836
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.